At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed melanoma that is metastatic or unresectable
- ✓Measurable disease: at least 1 lesion ≥20 mm (conventional) or ≥10 mm (spiral CT) within 4 weeks prior to enrollment
- ✓No prior therapy or 1 prior treatment (cytokine/chemotherapy/combination) for metastatic disease
- ✓Age ≥18 years
- ✕Known brain metastases
- ✕Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to enrollment
- ✕Currently receiving any other investigational agents
- ✕History of allergic reactions to compounds of similar chemical or biologic composition to vorinostat
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Vorinostat in Patients With Advanced Melanoma
In Brief
A Phase 2 clinical trial evaluating vorinostat for Ciliary Body and Choroid Melanoma, Medium/Large Size and 6 related conditions. Completed, enrolled 32 participants across 5 sites in 2 countries.
Detailed Summary
This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Timeline
Interventions
Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.